Current position

Cathie Wood’s Prime Medicine Inc (PRME) position

Reported position history, portfolio importance and verified filing changes from public SEC disclosures.

ARK Investment ManagementVerified through Q2 2026
Relationship snapshot

At a glance

The full verified relationship, including prior ownership episodes and exits where supported.

First reportedQ4 2022Earliest verified positive filing snapshot
Latest statusCurrent positionBased on the latest supported relationship state
Peak shares8.35MHighest verified quarter-end share count
Quarters reported15Verified quarters with shares above zero
What happened?

ARK Investment Management first reported Prime Medicine Inc in Q4 2022. The reported position was increased and reduced across later filings. ARK Investment Management currently reports 8.35M shares. The latest verified filing showed: Bought 33.6% more.

Verified SEC history

Position over time

See the same verified relationship through reported shares, portfolio weight or reported value.

Metric

Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.

Key filing events

What changed

Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.

Q2 2026
Bought 33.6% more+2.10M shares · 8.35M shares reported after the change
Filing context

Quarter-end price $3.69 · Estimated holding basis $6.40

Q1 2026
Bought 16.4% more+878.30K shares · 6.25M shares reported after the change
Filing context

Quarter-end price $3.48 · Estimated holding basis $7.31

Q4 2025
Sold 2.0% of the position−109.33K shares · 5.37M shares remained
Filing context

Quarter-end price $3.47 · Estimated holding basis $7.94

Q3 2025
Bought 135.8% more+3.16M shares · 5.48M shares reported after the change
Filing context

Quarter-end price $5.54 · Estimated holding basis $7.94

Q2 2025
Sold 25.0% of the position−772.50K shares · 2.32M shares remained
Filing context

Quarter-end price $2.47 · Estimated holding basis $11.19

Q1 2025
Sold 39.9% of the position−2.06M shares · 3.10M shares remained
Filing context

Quarter-end price $1.99 · Estimated holding basis $11.19

Portfolio importance

How important is Prime Medicine Inc in ARK Investment Management’s reported portfolio?

Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.

Current portfolio weight0.2%Q2 2026
Current rank#80of 190 reported positions
Peak portfolio weight0.3%Q1 2024
Best historical rank#51Q2 2023
At peak importanceQ1 2024
PRME
0.3%
Largest holding
8.1%
SEC evidence & methodology

SEC filing evidence

Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.

Latest verified stock price$3.002026-09-16

Market context only; not an investor transaction price.

Latest filing quarter-end price$3.69Q2 2026

Derived from validated reported value and shares where supported.

Estimated holding basis$6.40Historical reference — not actual purchase price

Calculated from supported filing history.

Latest verified investor filingQ2 2026 · filed 2026-08-14
Open SEC filing ↗

This tracker follows ARK Investment Management’s aggregated Form 13F disclosures. It is not Cathie Wood’s personal brokerage account, and 13F filings do not reveal exact trade dates or execution prices.